Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Baxter
US Department of Justice
US Army
Dow
Johnson and Johnson
Citi
Medtronic
Colorcon

Generated: June 25, 2018

DrugPatentWatch Database Preview

LEXAPRO Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Lexapro patents expire, and when can generic versions of Lexapro launch?

Lexapro is a drug marketed by Allergan Sales Llc and is included in two NDAs. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has fifty-six patent family members in thirty-eight countries.

The generic ingredient in LEXAPRO is escitalopram oxalate. There are twenty-six drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the escitalopram oxalate profile page.
Drug patent expirations by year for LEXAPRO
Pharmacology for LEXAPRO
Synonyms for LEXAPRO
(+)-(S)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
(+)-(S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile oxalate
(+)-(S)-Citalopram
(+)-(S)-Citalopram oxalate
(+)-Citalopram
(1r)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-3h-isobenzofuran-5-carbonitrile
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
(1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile Ethanedioate
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; oxalic acid
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile;oxalic acid
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-isobenzofuran-5-carbonitrile
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-isobenzofuran-5-carbonitrile; oxalic acid
(S)-(+)-1-[3-(dimethylamino) propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile
(S)-(+)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile
(S)-(+)-Citalopram Oxalate
(S)-(+)Citalopram oxalate
(s)-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
(S)-1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile oxalate
(s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5 carbonitrile
(S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile Oxalate
(S)-Citalopram
(S)-Citalopram Oxalate
1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
118335-EP2275420A1
118335-EP2298764A1
118335-EP2298765A1
128196-01-0
219861-08-2
4O4S742ANY
5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, (1S)-
5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, (1S)-, ethanedioate (1:1)
5U85DBW7LO
68P
861E082
AB0012102
AB00698374_10
AB00698374-07
AB00698374-09
AC-4508
AC-6770
AC1L3TGW
AC1L3TGZ
AJ-45648
AK138215
AK322039
AKOS016340275
AKOS017343470
AN-11923
AN-13009
AN-14764
AN-9671
AOB4715
API0010346
AX8019428
BDBM50302225
BG0433
BIDD:PXR0135
BRD-K70301876-034-02-0
BSPBio_002644
C22H23FN2O5
CAS-219861-08-2
cc-372
CCG-39559
CHEBI:36791
CHEMBL1200322
CHEMBL1508
Cipralex
Cipralex (TN)
Citalopram Oxalate
CPD000469191
CS-2053
CS-2054
CTK8E9353
D02567
D07913
D08RBC
DB01175
DR001465
DSSTox_CID_26003
DSSTox_GSID_46003
DSSTox_RID_81282
DTXSID1046003
DTXSID8048440
E0958
EBD32686
Entact
Escitalopram
Escitalopram (INN)
Escitalopram (oxalate)
Escitalopram [INN:BAN]
Escitalopram [INN]
Escitalopram for system suitability, EuropePharmacopoeia (EP) Reference Standard
Escitalopram oxalate
Escitalopram oxalate (JAN/USAN)
Escitalopram oxalate [USAN:USP]
Escitalopram oxalate [USAN]
escitalopram oxalate inn
Escitalopram oxalate, >=98% (HPLC), powder
Escitalopram oxalate, EuropePharmacopoeia (EP) Reference Standard
Escitalopram oxalate, United States Pharmacopeia (USP) Reference Standard
escitalopramum
Esertia
Esertia (TN)
FT-0650410
FT-0660873
Gaudium
GTPL7177
HE305186
HMS2051D11
HMS2089O08
HMS2231M16
HMS3370I17
HMS3393D11
HY-14258
HY-14258A
J-005570
J90016
KB-62485
KBio2_001881
KBio2_004449
KBio2_007017
KBio3_001864
KBioGR_001644
KBioSS_001881
KS-1263
KTGRHKOEFSJQNS-BDQAORGHSA-N
Lexapro (TN)
Lopac-C-7861
LS-183517
LS-183519
Lu 26-054-0
Lu-26-054-0
LU-260540
MFCD06407826
MLD-55
MLS001401408
MolPort-003-666-613
MRF-0000226
NC00194
NCGC00015267-01
NCGC00015267-02
NCGC00015267-03
NCGC00015267-06
NCGC00025160-01
NCGC00095903-01
NCGC00178555-01
NCGC00178555-02
NSC-758934
NSC758934
Pharmakon1600-01505216
R-Citalopram
RT-012495
S-(+)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile oxalate
S-(+)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile oxalate
S-(+)-5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, oxalate
S-(+)-Citalopram
S-(+)-Citalopram oxalate
S(+)-Citalopram
SAM001246668
SC-47288
SCHEMBL34948
SCHEMBL35123
Seroplex
SMR000469191
SPBio_000621
Spectrum_001401
SPECTRUM1505216
Spectrum2_000551
Spectrum3_001062
Spectrum4_001212
Spectrum5_001693
ST24046691
TL8001823
Tocris-1427
Tox21_111535
Tox21_111535_1
UNII-0DHU5B8D6V component WSEQXVZVJXJVFP-FQEVSTJZSA-N
UNII-4O4S742ANY
UNII-5U85DBW7LO
UNII-B5RDX2419X component KTGRHKOEFSJQNS-BDQAORGHSA-N
WSEQXVZVJXJVFP-FQEVSTJZSA-N
ZINC3800706

US Patents and Regulatory Information for LEXAPRO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc LEXAPRO escitalopram oxalate SOLUTION;ORAL 021365-001 Nov 27, 2002 AA RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan Sales Llc LEXAPRO escitalopram oxalate TABLET;ORAL 021323-003 Aug 14, 2002 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Sales Llc LEXAPRO escitalopram oxalate TABLET;ORAL 021323-002 Aug 14, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Sales Llc LEXAPRO escitalopram oxalate TABLET;ORAL 021323-001 Aug 14, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for LEXAPRO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc LEXAPRO escitalopram oxalate TABLET;ORAL 021323-002 Aug 14, 2002 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc LEXAPRO escitalopram oxalate TABLET;ORAL 021323-003 Aug 14, 2002 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc LEXAPRO escitalopram oxalate SOLUTION;ORAL 021365-001 Nov 27, 2002 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc LEXAPRO escitalopram oxalate TABLET;ORAL 021323-001 Aug 14, 2002 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for LEXAPRO
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Capsules 5 mg ➤ Subscribe 2005-08-17
➤ Subscribe Capsules 10 mg and 20 mg ➤ Subscribe 2005-03-30

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for LEXAPRO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/049 United Kingdom ➤ Sign Up PRODUCT NAME: ESCITALOPRAM OXALATE; REGISTERED: SE 17084/85/86/87 20011207; UK PL 13761/0008 20020610; UK PC 13761/0009 20020610; UK PL 13761/0010 20020610; UK PL 13761/0011 20020610; UK PL 13761/0012 20020610; UK PL 13761/0013 20020610; UK PL 13761/00014 20020610; UK PL 13761/0015 20020610
/2002 Austria ➤ Sign Up PRODUCT NAME: ESCITALOPRAM UND DESSEN NICHT-TOXISCHE SAEUREADDITIONSSALZE; NAT. REGISTRATION NO/DATE: 1-24549, 1-24550, 1-24551, 1-24552 20020618; FIRST REGISTRATION: SE 17084, 17085, 17086,17087 20011207
00155 Netherlands ➤ Sign Up PRODUCT NAME: ESCITALOPRAM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER ESCITALOPRAMOXALAAT; REGISTRATION NO/DATE: RVG 30490 - RVG 30497 20040427
02C/039 Belgium ➤ Sign Up PRODUCT NAME: ESCITALOPRAM. OXALAT. (INN) ESCITALOPRAM; NATL. REGISTRATION NO/DATE: 7004 IE10 F 3 20020729; FIRST REGISTRATION: SE 17084 20011207
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Johnson and Johnson
Colorcon
Daiichi Sankyo
Fish and Richardson
Citi
Dow
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.